Theravance Biopharma (TBPH) Deferred Taxes (2024 - 2026)
Theravance Biopharma (TBPH) posted quarterly Deferred Taxes of -$3.0 million for Q1 2026, down 61.93% year-over-year from -$7.9 million in Q1 2025, and down 10096.67% quarter-over-quarter from $30000.0 in Q4 2025.
Theravance Biopharma (TBPH) Deferred Taxes (2024 - 2026) Analysis & Trends
Theravance Biopharma (TBPH) has reported Deferred Taxes for 3 consecutive years, with -$3.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Deferred Taxes fell 61.93% year-over-year to -$3.0 million; the TTM figure through Mar 2026 stood at -$12.7 million (down 42.12% YoY), while the FY2025 annual figure was -$11.5 million, down 52.11% from the prior year.
- Deferred Taxes slipped to -$3.0 million in Q1 2026 per TBPH's latest filing, from $30000.0 in the prior quarter.
- Across five years, Deferred Taxes topped out at $994000.0 in Q3 2025 and bottomed at -$10.7 million in Q2 2025.
- Historically, Deferred Taxes has averaged -$2.5 million across 3 years, with a median of -$561000.0 in 2024.
- On a YoY basis, Deferred Taxes climbed as much as 1004.44% in 2025 and fell as far as 1805.7% in 2025.
- Theravance Biopharma's Deferred Taxes stood at -$6.6 million in 2024, then soared by 100.46% to $30000.0 in 2025, then slumped by 10096.67% to -$3.0 million in 2026.
- Business Quant data shows TBPH's Deferred Taxes at -$3.0 million in Q1 2026, $30000.0 in Q4 2025, and $994000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Deferred Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -69.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 194.40 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -137,876.64 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 2.66 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Theravance Biopharma | 880.59 Mn | 492.93 Mn | - | -218,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -218,000.00 |
| Mar 31, 2026 | -3.00 Mn |
| Dec 31, 2025 | 30,000.00 |
| Sep 30, 2025 | 994,000.00 |
| Jun 30, 2025 | -10.69 Mn |
| Mar 31, 2025 | -1.85 Mn |
| Dec 31, 2024 | -6.59 Mn |
| Sep 30, 2024 | 90,000.00 |
| Jun 30, 2024 | -561,000.00 |
| Mar 31, 2024 | -513,000.00 |